Good morning :)
Venus Remedies Ltd

Venus Remedies Ltd

VENUSREM Share Price

NSE
₹651.453.12% (-20.95)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹870 cr, stock is ranked 1,532

High Risk

Stock is 4.04x as volatile as Nifty

VENUSREM Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹870 cr, stock is ranked 1,532

High Risk

Stock is 4.04x as volatile as Nifty

VENUSREM Performance & Key Metrics

VENUSREM Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
11.411.55—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.675.790.58%

VENUSREM Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

VENUSREM Company Profile

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.

VENUSREM Similar Stocks (Peers)

Compare with peers Compare with peers 

VENUSREM Similar Stocks (Peers)

Compare with peers Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
38.47
38.47
1Y Return
10.56%
10.56%
Buy Reco %
94.29
94.29
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
77.37
77.37
1Y Return
47.65%
47.65%
Buy Reco %
81.48
81.48
Cipla Ltd
CIPLA
PE Ratio
20.71
20.71
1Y Return
3.97%
3.97%
Buy Reco %
54.84
54.84
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
19.06
19.06
1Y Return
15.61%
15.61%
Buy Reco %
48.39
48.39
Lupin Ltd
LUPIN
PE Ratio
32.19
32.19
1Y Return
18.34%
18.34%
Buy Reco %
72.22
72.22
Compare with Peers

VENUSREM Forecast

VENUSREM Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

VENUSREM

VENUSREM

Income

Balance Sheet

Cash Flow

VENUSREM Income Statement

VENUSREM Income Statement

Loading...

Quartersep 2023dec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025
Total Revenue170.77145.77199.08110.20178.03188.80201.73140.59194.46182.78
Operating & Other expensessubtract149.93131.38175.6997.35162.53158.50165.97121.80161.79142.74
Depreciation/Amortizationsubtract6.446.545.915.986.415.414.716.186.176.56
Interest & Other Itemssubtract0.060.070.020.020.020.010.010.010.010.01
Taxes & Other Itemssubtract4.400.936.955.635.565.2810.043.006.367.89
EPS7.445.137.860.922.6314.6615.717.1815.0619.14
See Costs

EPS in ₹. Other numbers in ₹ cr

VENUSREM Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

VENUSREM Stock Peers

VENUSREM Past Performance & Peer Comparison

VENUSREM Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Venus Remedies Ltd19.221.55—
Sun Pharmaceutical Industries Ltd38.475.800.91%
Torrent Pharmaceuticals Ltd77.3719.480.73%
Cipla Ltd20.713.491.18%

VENUSREM Stock Price Comparison

Compare VENUSREM with any stock or ETF
Compare VENUSREM with any stock or ETF
VENUSREM
Loading...

VENUSREM Holdings

VENUSREM Shareholdings

VENUSREM Promoter Holdings Trend

VENUSREM Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

VENUSREM Institutional Holdings Trend

VENUSREM Institutional Holdings Trend

Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.15%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

VENUSREM Shareholding Pattern

VENUSREM Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding41.76%0.00%1.03%2.26%54.96%

Mar 2025

Jun 2025

Sep 2025

Dec 2025

VENUSREM Shareholding History

VENUSREM Shareholding History

SepDec '24MarJunSepDec '251.18%1.11%1.34%2.24%1.86%2.26%

VENUSREM Insider Trades & Bulk Stock Deals

VENUSREM Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing VENUSREM stock

smallcases containing VENUSREM stock

Looks like this stock is not in any smallcase yet.

VENUSREM Events

VENUSREM Events

VENUSREM Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

VENUSREM has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

VENUSREM Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

VENUSREM has not given any dividends in last 5 years

VENUSREM Upcoming Dividends

VENUSREM Upcoming Dividends

No upcoming dividends are available

VENUSREM Past Dividends

VENUSREM Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2013

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 23, 2013

Cash Dividend

Ex DateEx DateSep 20, 2012

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 20, 2012

Cash Dividend

Ex DateEx DateSep 22, 2011

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 22, 2011

Cash Dividend

Ex DateEx DateSep 23, 2010

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 23, 2010

VENUSREM Stock News & Opinions

VENUSREM Stock News & Opinions

Earnings
Venus Remedies consolidated net profit rises 30.51% in the December 2025 quarter

Net profit of Venus Remedies rose 30.51% to Rs 25.58 crore in the quarter ended December 2025 as against Rs 19.60 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 180.26 crore in the quarter ended December 2025 as against Rs 176.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.26176.52 2 OPM %20.8110.21 - PBDT40.0320.38 96 PBT33.4714.97 124 NP25.5819.60 31 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Venus Remedies to hold board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Venus Remedies receives marketing authorisation for Ceftazidime + Avibactam in Indonesia

Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the Company in Indonesia. The product is indicated for the treatment of serious infections caused by multi-drug resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infectionsPowered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Venus Remedies Ltd leads gainers in 'B' group

Zuari Industries Ltd, Vipul Ltd, Orient Ceratech Ltd and Urban Company Ltd are among the other gainers in the BSE's 'B' group today, 11 November 2025.Venus Remedies Ltd spiked 14.69% to Rs 538 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 27045 shares were traded on the counter so far as against the average daily volumes of 1651 shares in the past one month. Zuari Industries Ltd soared 12.02% to Rs 343. The stock was the second biggest gainer in 'B' group. On the BSE, 66349 shares were traded on the counter so far as against the average daily volumes of 13731 shares in the past one month. Vipul Ltd surged 9.89% to Rs 9.33. The stock was the third biggest gainer in 'B' group. On the BSE, 30899 shares were traded on the counter so far as against the average daily volumes of 64353 shares in the past one month. Orient Ceratech Ltd added 9.71% to Rs 39.09. The stock was the fourth biggest gainer in 'B' group. On the BSE, 54188 shares were traded on the counter so far as against the average daily volumes of 5194 shares in the past one month. Urban Company Ltd jumped 8.11% to Rs 143.95. The stock was the fifth biggest gainer in 'B' group. On the BSE, 11.44 lakh shares were traded on the counter so far as against the average daily volumes of 6.48 lakh shares in the past one month. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 473.50% in the September 2025 quarter

Net profit of Venus Remedies rose 473.50% to Rs 20.13 crore in the quarter ended September 2025 as against Rs 3.51 crore during the previous quarter ended September 2024. Sales rose 13.32% to Rs 192.75 crore in the quarter ended September 2025 as against Rs 170.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales192.75170.10 13 OPM %16.064.45 - PBDT32.6615.48 111 PBT26.499.07 192 NP20.133.51 474 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Venus Remedies to convene board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 686.89% in the June 2025 quarter

Net profit of Venus Remedies rose 686.89% to Rs 9.60 crore in the quarter ended June 2025 as against Rs 1.22 crore during the previous quarter ended June 2024. Sales rose 21.44% to Rs 131.90 crore in the quarter ended June 2025 as against Rs 108.61 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales131.90108.61 21 OPM %7.6610.37 - PBDT18.7812.83 46 PBT12.606.85 84 NP9.601.22 687 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Venus Remedies to table results

Venus Remedies will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Venus Remedies to hold AGM

Venus Remedies announced that the 36th Annual General Meeting(AGM) of the company will be held on 22 August 2025.Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Venus Remedies to conduct board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025.Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Venus Remedies Ltd (VENUSREM) today?

    The share price of VENUSREM as on 2nd March 2026 is ₹651.45. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Venus Remedies Ltd (VENUSREM) share?

    The past returns of Venus Remedies Ltd (VENUSREM) share are
    • Past 1 week: -13.54%
    • Past 1 month: -21.98%
    • Past 3 months: -14.65%
    • Past 6 months: 40.78%
    • Past 1 year: 127.10%
    • Past 3 years: 286.16%
    • Past 5 years: 193.25%

  3. What are the peers or stocks similar to Venus Remedies Ltd (VENUSREM)?

    The peers or stocks similar to Venus Remedies Ltd (VENUSREM) include:

  4. What is the market cap of Venus Remedies Ltd (VENUSREM) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venus Remedies Ltd (VENUSREM) is ₹870.79 Cr as of 2nd March 2026.

  5. What is the 52 week high and low of Venus Remedies Ltd (VENUSREM) share?

    The 52-week high of Venus Remedies Ltd (VENUSREM) is ₹839.95 and the 52-week low is ₹277.95.

  6. What is the PE and PB ratio of Venus Remedies Ltd (VENUSREM) stock?

    The P/E (price-to-earnings) ratio of Venus Remedies Ltd (VENUSREM) is 19.22. The P/B (price-to-book) ratio is 1.55.

  7. Which sector does Venus Remedies Ltd (VENUSREM) belong to?

    Venus Remedies Ltd (VENUSREM) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Venus Remedies Ltd (VENUSREM) shares?

    You can directly buy Venus Remedies Ltd (VENUSREM) shares on Tickertape. Simply sign up, connect your demat account and place your order.